|
시장보고서
상품코드
2077569
재발성 또는 난치성 미만성 거대 B세포 림프종 시장 : 약제 유형별, 유통 채널별, 지역별Relapsed or Refractory Diffuse Large B Cell Lymphoma Market, By Drug Type, By Distribution Channel, By Geography |
||||||
재발성 또는 난치성 미만성 거대 B세포 림프종 시장은 2026년에 16억 8,240만 달러 규모가 될 것으로 추정되며, 2033년까지 22억 8,960만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 4.5%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 16억 8,240만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간 CAGR: | 4.50% | 2033년 시장 규모 예측: | 22억 8,960만 달러 |
시장 관계자들은 재발성 또는 난치성 미만성 거대 B세포 림프종 치료를 위한 효과적인 치료법 개발에 주력하고 있으며, 이는 예측 기간 동안 시장 성장을 견인할 것으로 전망됩니다. 예를 들어, 2020년 11월, 임상 개발의 후기 단계에 있는 생명공학 기업인 ADC Therapeutics SA는 론카스토크시맙 테실린(Lonca)에 대한 생물학적 제제 승인 신청(BLA)이 미국 식품의약국(FDA)에 접수되었다고 발표했습니다. 론카스토크시맙 테실린(Lonca)은 재발성 또는 난치성 미만성 거대 B세포 림프종(DLBCL)의 치료를 목적으로 개발되고 있습니다.
또한, 2020년 12월, 노바티스 AG는 제2상 JULIET 임상시험에서 추적 관찰 기간 중앙값 40개월에 대한 분석 결과를 발표했습니다. 이에 따르면, CAR-T 세포 치료법인 '킴리아(Kymriah)'는 재발성 또는 난치성 미만성 거대 B세포 림프종(DLBCL) 환자에서 안전성과 유효성을 입증했습니다.
시장 역학
시장에 진출한 각 기업은 시장 내 입지를 강화하기 위해 제휴 및 계약과 같은 다양한 비유기적 성장 전략에 주력하고 있으며, 이는 재발성 또는 난치성 미만성 거대 B세포 림프종 시장의 성장을 견인할 것으로 예상됩니다. 예를 들어, 2020년 6월 10일, 상장 바이오의약품 기업인 애브비(AbbVie Inc.)와 생명공학 기업인 젠맙(Genmab A/S)은 젠맙이 보유한 암 치료용 초기 단계 항체 후보 물질의 개발 및 상용화에 관한 제휴 계약을 체결했습니다. 본 계약에 따라 양사는 미만성 거대 B세포 림프종(DLBCL), 만성 림프구성 백혈병(CLL), 여포성 림프종(FL), 맨틀세포 림프종(MCL) 등의 B세포 악성 종양을 적응증으로 하는 에프코리타맙을 상용화하게 됩니다.
마찬가지로, 2020년 6월 29일, 제약사 Karyopharm Therapeutics, Inc.는 맥케슨 코퍼레이션 산하의 독립 전문 약국인 Biologics by McKesson을 통해, 재발성 또는 난치성 미만성 거대 B세포 림프종(RR DLBCL) 성인 환자 치료를 적응증으로 하는 'XPOVIO'의 전문 약국 제공업체로 선정했습니다.
본 조사의 주요 특징:
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트도 제공하고 있습니다.
- 본 조사에서는 다음의 매개변수를 바탕으로, 전 세계 재발성 또는 난치성 미만성 거대 B세포 림프종 시장의 주요 기업 개요을 작성하고 있습니다. 구체적으로는 기업 개요, 재무 실적, 제품 포트폴리오, 시장 내 입지, 유통 전략, 주요 발전 사항, 전략 및 향후 계획입니다.
- 본 보고서에서 얻을 수 있는 인사이트는 각 기업의 마케팅 담당자 및 경영진이 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략과 관련하여 정보에 기반한 의사결정을 내리는 데 도움이 됩니다.
- 본 '세계 재발성 또는 난치성 미만성 거대 B세포 림프종 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자 여러분은 전 세계 재발성 또는 난치성 미만성 거대 B세포 림프종 시장 분석에 활용되는 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 재발성 또는 난치성 미만성 거대 B세포 림프종 시장 : 약물 유형별, 2021-2033년
제5장 세계의 재발성 또는 난치성 미만성 거대 B세포 림프종 시장 : 유통 채널별, 2021-2033년
제6장 세계의 재발성 또는 난치성 미만성 거대 B세포 림프종 시장 : 지역별, 2021-2033년
제7장 경쟁 구도
제8장 섹션
KSM 26.07.08Relapsed or Refractory Diffuse Large B-cell Lymphoma Market is estimated to be valued at USD 1,682.4 Mn in 2026 and is expected to reach USD 2,289.6 Mn by 2033, growing at a compound annual growth rate (CAGR) of 4.5% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 1,682.4 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 4.50% | 2033 Value Projection: | USD 2,289.6 Mn |
Market players are focusing on developing effective therapies for the treatment of relapsed or refractory diffuse large B-cell lymphoma which is expected to fuel the market growth over the forecast period. For instance, in November 2020, ADC Therapeutics SA, a late clinical-stage biotechnology company, announced that its Biologics License Application (BLA) for loncastuximab tesirine (Lonca) had been accepted by the U.S. Food and Drug Administration (FDA). Lloncastuximab tesirine (Lonca) is developed for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Moreover, in December 2020, Novartis AG, announced analyses of a 40-month median follow-up from the Phase II JULIET trial, according to which Kymriah, a CAR-T cell therapy, showed safety and efficacy in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
Market Dynamics
Market players are focusing on various inorganic growth strategies such as collaborations and agreements in order to strengthen their market presence which is anticipated to drive the growth of relapsed or refractory diffuse large B-cell lymphoma market. For instance, on June 10, 2020, AbbVie Inc., a publicly traded biopharmaceutical company and Genmab A/S, a biotechnology company, signed a collaboration agreement to develop and commercialize Genmab's early-stage investigational antibody product candidates for cancer. Under this agreement, the companies will commercialize epcoritamab, indicated for B cell malignancies such as diffuse large B cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and mantle cell lymphoma (MCL).
Similarly, on June 29, 2020, Karyopharm Therapeutics, Inc., a pharmaceutical company, selected Biologics by McKesson, an independent specialty pharmacy by McKesson Corporation, as a specialty pharmacy provider for XPOVIO, indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (RR DLBCL)
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global relapsed or refractory diffuse large B-cell lymphoma market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include MorphoSys US Inc., Bristol Myers Squibb, Karyopharm Therapeutics, F. Hoffmann-La Roche AG, Merck & Co., Inc., Gilead Sciences, Inc., and Novartis AG.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global relapsed or refractory diffuse large B-cell lymphoma market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global relapsed or refractory diffuse large B-cell Lymphoma market.
Detailed Segmentation:
- Global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market, By Drug Type (Revenue, USD Mn, 2021 - 2033)
- Monjuvi
- XPOVIO
- Polivy
- Kymriah
- Yescarta
- Others
- Global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market, By Region (Revenue, USD Mn, 2021 - 2033)
- North America
- By Drug Type
- Monjuvi
- XPOVIO
- Polivy
- Kymriah
- Yescarta
- Others
- By Distribution Channel:
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- U.S.
- Canada
- By Drug Type
- Latin America
- By Drug Type
- Monjuvi
- XPOVIO
- Polivy
- Kymriah
- Yescarta
- Others
- By Distribution Channel:
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Drug Type
- Europe
- By Drug Type
- Monjuvi
- XPOVIO
- Polivy
- Kymriah
- Yescarta
- Others
- By Distribution Channel:
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- By Drug Type
- Asia Pacific
- By Drug Type
- Monjuvi
- XPOVIO
- Polivy
- Kymriah
- Yescarta
- Others
- By Distribution Channel:
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Drug Type
- Middle East
- By Drug Type
- Monjuvi
- XPOVIO
- Polivy
- Kymriah
- Yescarta
- Others
- By Distribution Channel:
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Drug Type
- Africa
- By Drug Type
- Monjuvi
- XPOVIO
- Polivy
- Kymriah
- Yescarta
- Others
- By Distribution Channel:
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Drug Type
- Company Profiles
- MorphoSys US Inc.*
- Company Overview
- Material Portfolio
- Financial Performance
- Key Highlights
- Market Strategies
- Bristol Myers Squibb
- Karyopharm Therapeutics
- Hoffmann-La Roche AG
- Merck & Co., Inc.
- Gilead Sciences, Inc.
- Novartis AG
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Trends
- Recent Product Launches/Approvals
- Mergers, Acquisitions, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
- PORTER's Analysis
4. Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market, By Drug Type, 2021-2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Monjuvi
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
- XPOVIO
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
- Segment Trends
- Polivy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
- Segment Trends
- Kymriah
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
- Segment Trends
- Yescarta
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
- Segment Trends
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
- Segment Trends
5. Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market, By Distribution Channel, 2021-2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Hospitals Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
6. Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market, By Region, 2021-2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, a By Drug Type, 2021-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, a By Drug Type, 2021-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, a By Drug Type, 2021-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, a By Drug Type, 2021-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, a By Drug Type, 2021-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, a By Drug Type, 2021-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021-2033, (US$ Mn)
- North Africa
- Central Africa
- South Africa
7. Competitive Landscape
- Company Profiles
- MorphoSys US Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Bristol-Myers Squibb Company
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Karyopharm Therapeutics
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- F. Hoffmann-La Roche AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Merck & Co., Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Gilead Sciences, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Novartis AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Regeneron Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Cellular Biomedicine Group Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Genmab A/S
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Incyte
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- AbbVie Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Janssen Biotech, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- IMV Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Overland Pharmaceuticals (CY) Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- ADC Therapeutics SA
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Eagle Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Adaptive Biotechnologies Corporation
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- MorphoSys US Inc.
- Analysts' Views
8. Section
- References
- Research Methodology
- About us and Sales Contact
